Merus N.V.
Merus N.V., a pioneering biotechnology company headquartered in the Netherlands, focuses on the development of innovative bispecific antibody therapeutics. Founded in 2003, Merus has established itself as a leader in the biopharmaceutical industry, particularly in the fields of oncology and immunology. The company’s unique proprietary technology platform, known as the Biclonics® platform, enables the creation of bispecific antibodies that can simultaneously target multiple antigens, offering potential advantages in treating complex diseases. With a strong presence in Europe and North America, Merus has achieved significant milestones, including successful clinical trials and strategic partnerships with major pharmaceutical companies. The company’s commitment to advancing cancer treatment through its core products positions it as a notable player in the competitive biotech landscape, dedicated to improving patient outcomes and transforming therapeutic approaches.
DitchCarbon Score
How does Merus N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Merus N.V.'s score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Merus N.V.'s reported carbon emissions
Merus N.V., headquartered in the Netherlands, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Merus N.V. does not inherit emissions data from any parent or related organizations, meaning all information is self-reported and reflects their current status in climate commitments. Without specific emissions data or reduction initiatives, it is unclear how the company is addressing its carbon footprint or contributing to climate action within the biopharmaceutical industry. In the absence of concrete data, it is essential for Merus N.V. to establish clear climate commitments and reduction targets to align with industry standards and demonstrate accountability in their environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Merus N.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
